Skip to content

Immutep (IMMP) Stock Surges On Improving Study Results

Sam Boughedda trader
Updated 18 Sep 2020

Practice Stock Trading
Immutep IMMP stock Price

Biotechnology company Immutep (NASDAQ: IMMP) has announced encouraging interim data from its ongoing Phase 2 TACTI-002.

The company released an update on Thursday evening stating that they were encouraged by the results of the study which is being conducted with Merck & Co Inc.

The study is evaluating the combination of Immutep’s lead product eftilagimod alpha with Merck’s KEYTRUDA in patients with 2nd line head and neck squamous cell carcinoma or non-small cell lung cancer.

“We are very encouraged by the results in this patient group with resistant late stage Head & Neck Cancers where the likelihood of response to other treatments is small.

“The durability of responses and the two patients with a complete response are extremely promising signals and this combination should be further investigated,” said the Principal investigator, Dr Martin Forster, University College London Hospital.

Immutep shares…

Immutep ($IMMP)

The news has seen Immutep’s US-listed stock price significantly increase premarket on Friday. Having closed Thursday’s trading session at $1.60, it is currently trading 10.62% higher at $1.77 ahead of the open.


Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.